Translational Research Program 2022-2023

The LLS is seeking applications in the following priority areas:

1. Personalized medicine approach for cancer treatment. 

2. Development of novel therapies and/or novel therapeutic strategies.

3. Improvements in the safety and efficacy of stem cell transplantation.

4. Long-term outcome assessment following therapies.

5. New strategies for treatment of immunocompromised blood cancer patients in the era of infectious disease including SARS-CoV-2 and other emerging viruses.

Special topics of interest for this year: 

• Novel immunotherapy approaches and understanding novel immune synapses relevant to blood cancers

• Progress in understanding cancer cell/microenvironment interactions especially in the context of translation to novel therapies

   

Funding: $200,000 per year
Duration: 3 years

Research Authority due date: 21.10.21
LOI (required) due date: 29.10.21
Full proposal due date: 21.1.22